ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

NATPARA
Secondary hyperparathyroidism or hypocalcemia
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

NATPARA Rx

Generic Name and Formulations:
Parathyroid hormone (recombinant) 25mcg, 50mcg, 75mcg, 100mcg; lyophilized pwd for SC inj after reconstitution.

Company:
Shire US, Inc.

Therapeutic Use:

Indications for NATPARA:

Adjunct to calcium and vitamin D to control hypocalcemia in hypoparathyroidism.

Limitations Of use:

Use only for patients uncontrolled on calcium supplements and active vitamin D alone. Not studied in hypoparathyroidism caused by calcium-sensing receptor mutations or in acute post-surgical hypoparathyroidism.

Adult:

Individualize based on total serum calcium (albumin-corrected) and 24hr urinary calcium excretion. Give as SC inj in the thigh (alternate thigh daily). Initially 50mcg once daily; may increase in increments of 25mcg every 4 weeks up to max 100mcg daily, if serum calcium is not maintained >8mg/dL. May decrease to 25mcg daily if serum calcium repeatedly >9mg/dL. If currently receiving active vitamin D: decrease vitamin D dose by 50% if serum calcium >7.5mg/dL. Maintenance: use lowest dose to achieve total serum calcium within the lower half of the normal range (approx. 8–9mg/dL). See full labeling.

Children:

<18yrs: not established.

Warnings/Precautions:

Confirm sufficient 25-hydroxyvitamin D stores and serum calcium >7.5mg/dL prior to initiation. Risk of osteosarcoma; avoid in Paget's disease of bone, unexplained elevations of alkaline phosphatase, pediatric and young adults with open epiphyses, hereditary disorders predisposing to osteosarcoma, history of external beam or implant radiation therapy involving the skeleton. Measure calcium concentration every 3–7 days after starting therapy and when adjusting Natpara, active vitamin D, or calcium supplement doses; consider holding and/or reducing dose if severe hypercalcemia occurs. Renal impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Concomitant alendronate: not recommended. Concomitant digoxin: monitor serum calcium and digoxin levels and for digitalis toxicity; adjustments may be needed for both drugs.

Pharmacological Class:

Hormone.

Adverse Reactions:

Paresthesia, hypocalcemia, headache, hypercalcemia, nausea, hypoaesthesia, diarrhea, vomiting, arthralgia, hypercalciuria, pain in extremity; possibly osteosarcoma.

REMS:

YES

Generic Availability:

NO

How Supplied:

Multi-dose cartridges (dual-chamber)—2

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs